The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement

Salman OtoukeshGehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA;

Jianying ZhangDepartment of Information Sciences, City of Hope Medical Center, Duarte, CA, USA

Ryotaro NakamuraGehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA;

Anthony S. SteinGehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA;

Stephen J. FormanGehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA;

Guido MarcucciGehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA;

Vinod PullarkatGehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA;

Ibrahim AldossGehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA; Correspondence[email protected]

show all

The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date